In this column for The Wall Street Journal’s Think Tank, Drew Altman discusses a new Blue Cross Blue Shield Association report on “extreme price variation” in health care services and the limits of consumer information as a solution to the problem.
- view as grid
- view as list
In this column for The Wall Street Journal’s Think Tank, Drew Altman explores the data behind public concern about prescription drug costs and highlights that the people most in need are the most burdened by the problem.
In this column for The Wall Street Journal’s Think Tank, Drew Altman finds the public’s healthcare priorities have more to do with drug costs and other real world issues people deal with using the health care system than the ongoing partisan wrangling over the Affordable Care Act (ACA).
As the Build Back Better Act shifts from the House to the Senate, there’s considerable interest in provisions that would lower the cost of prescription drugs. The House-passed bill would allow the federal government to negotiate prices for some high-cost drugs in Medicare, and set a hard cap on out-of-pocket…
The “No Surprises Act,” which establishes new federal protections against most surprise out-of-network medical bills when a patient receives out-of-network services during an emergency visit or from a provider at an in-network hospital without advance notice, will take effect next month. A new KFF brief outlines what to expect in 2022.
In this column for The Wall Street Journal’s Think Tank, Drew Altman discusses new poll findings showing very small numbers of consumers are using provider quality and price information.
National health spending started to grow more rapidly recently after several years of unusually slow growth. This analysis from the Kaiser Family Foundation and the federal Bureau of Economic Analysis helps to dissect why that may be happening. Using recently-released disease-based health spending data compiled by the federal government, the analysis finds…
In his latest column for The Wall Street Journal’s Think Tank, Drew Altman explores how price is the major factor that distinguishes the cost of our health care system from those in other developed nations, yet most efforts in the U.S. to address health-care costs don’t focus on price much…